We are live on ! Find out more
SNOA icon

Sonoma Pharmaceuticals
SNOA

18 hedge funds and large institutions have $860K invested in Sonoma Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

0.11% less ownership

Funds ownership: 0.39% → 0.29% (-0.11%)

10% less funds holding

Funds holding: 20 → 18 (-2)

27% less capital invested

Capital invested by funds: $1.19M → $860K (-$326K)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
18
Holders Change
-2
Holders Change %
-10%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$143K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$19.9K
3
Morgan Stanley
Morgan Stanley
New York
+$13K
4
HFS
HBC Financial Services
Washington
+$1.92K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$152K
2
VF
Virtu Financial
New York
-$119K
3
Squarepoint
Squarepoint
New York
-$88K
4
UBS Group
UBS Group
Switzerland
-$6.52K
5
RE
RBC Europe
United Kingdom
-$6.21K

SNOA Hedge Fund Activity: Q4 2021 in Review

18 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q4 2021, worth a combined $860K — down 27% from $1.19M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of SNOA and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 3 added.

The largest buyer was Vanguard Group, adding an estimated $143K. The largest seller was Renaissance Technologies, cutting an estimated $152K.

  • 18 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q4 2021, down from 20 in Q3 2021.
  • Funds reported $860K of Sonoma Pharmaceuticals stock for Q4 2021, down 27% quarter-over-quarter.
  • 1 fund opened new Sonoma Pharmaceuticals positions in Q4 2021 and 3 closed out, a net change of -2 holders.
  • The largest Sonoma Pharmaceuticals buyer in Q4 2021 was Vanguard Group, an estimated $143K added.
  • The largest Sonoma Pharmaceuticals seller in Q4 2021 was Renaissance Technologies, an estimated $152K sold.

Based on aggregated 13F filings for Q4 2021.